Pharmacologic elevation of high-density lipoproteins: Recent insights on mechanism of action and atherosclerosis protection

Current Opinion in Cardiology

Volumn 19, Issue 4, 2004, Pages 366-373

  Meyers, C Daniel ^a   Kashyap, Moti L ^a,b  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apolipoprotein Al; Atherosclerosis; High density lipoproteins; Reverse cholesterol transport

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; APOLIPOPROTEIN A1; CHOLESTEROL ESTER TRANSFER PROTEIN; CIPROFIBRATE; DIMYRISTOYLPHOSPHATIDYLCHOLINE; FIBRIC ACID DERIVATIVE; GEMCABENE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PROTEIN INHIBITOR; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; ROSIGLITAZONE; ROSUVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CATABOLISM; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DYSLIPIDEMIA; ENDOTHELIUM; HUMAN; LIVER FUNCTION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTILIPEMIC AGENTS; APOLIPOPROTEIN A-I; ARTERIOSCLEROSIS; BIOLOGICAL TRANSPORT, ACTIVE; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, LDL; HUMANS; LIPOPROTEINS, HDL;

EID: 3142757959     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hco.0000126582.27767.87     Document Type: Review

References (53)

1. Kashyap ML, Tavintharan S, Kamanna VS: Optimal therapy of low levels of high density lipoprotein-cholesterol. Am J Cardiovasc Drugs 2003, 3:53-65. A review of the epidemiology, clinical trial evidence, and treatment of patients with low HDL.
2. Rader DJ: Regulation of reverse cholesterol transport and clinical implicalions. Am J Cardiol 2003, 92:42J-49J. Concise discussion of the genes that regulate RCT.
3. Hersberger M, von Eckardstein A: Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment. Drugs 2003, 63:1907-1945.
4. Martinez LO, Jacquet S, Esteve JP, et al.: Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature 2003, 421:75-79. Groundbreaking characterization of a previously unknown hepatic apoAI receptor that mediates HDL holoparticle endocytosis and catabolism. This receptor is an attractive site for drug inhibition.
5. Calabresi L, Gomaraschi M, Franceschini G: Endothelial protection by high-density lipoproteins: from bench to bedside. Arterioscler Thromb Vasc Biol 2003, 23:1724-1731. Thorough review of the atheroprotective properties of HDL unrelated to RCT.
6. Viles-Gonzalez JF, Fuster V, Corti R, et al.: Emerging importance of HDL cholesterol in developing high-risk coronary plaques in acute coronary syndromes. Curr Opin Cardiol 2003, 18:286-294.
7. Mackness MI, Mackness B, Durrington PN: Paraoxonase and coronary heart disease. Atheroscler Suppl 2002, 3:49-55.
8. Karasawa K, Harada A, Satoh N, et al.: Plasma platelet activating factor-acetylhydrolase (PAF-AH). Prog Lipid Res 2003, 42:93-114.
9. Hammad SM, Stefansson S, Twal WO, et al.: Cubilin, the endocytic receptor for intrinsic factor-vitamin B(12) complex, mediates high-density lipoprotein holoparticle endocytosis. Proc Natl Acad Sci U S A 1999, 96:10158-10163.
10. Tailleux A, Duriez P, Fruchart JC, et al.: Apolipoprotein A-II, HDL metabolism and atherosclerosis. Atherosclerosis 2002, 164:1-13.
11. Sakai T, Kamanna VS, Kashyap ML: Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. Arterioscler Thromb Vasc Biol 2001, 21:1783-1789.
12. Ganji SH, Kamanna VS, Kashyap ML: Niacin and cholesterol: role in cardiovascular disease (review). J Nutr Biochem 2003, 14:298-305.
13. Kamanna VS, Kashyap ML: Mechanism of action of niacin on lipoprotein metabolism. Curr Atheroscler Rep 2000, 2:36-46.
14. Malik S, Kashyap ML: Niacin, lipids, and heart disease. Curr Cardiol Rep 2003, 5:470-476. An up-to-date review of the molecular mechanisms of nicotinic acid.
15. Jin FY, Kamanna VS, Kashyap ML: Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells: implication for reverse cholesterol transport. Arterioscler Thromb Vasc Biol 1997, 17:2020-2028.
16. Morgan JM, Capuzzi DM, Baksh RI, et al.: Effects of extended-release niacin on lipoprotein subclass distribution. Am J Cardiol 2003, 91:1432-1436.
17. Asztalos BF, Batista M, Horvath KV, et al.: Change in alpha1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler Thromb Vasc Biol 2003, 23:847-852. HDL Atherosclerosis Treatment Study trial data showing that HDL subpopulation changes powerfully predict changes in angiographic coronary disease.
18. Ganji SH, Xing Y, Kamanna VS, et al.: Niacin selectively inhibits hepatocyte DGAT2 but not DGAT1, key enzymes for triglyceride synthesis. Arterioscler Thromb Vasc Biol 2003, 23:50a. Important characterization of the triglyceride-synthesizing enzyme directly inhibited by nicotinic acid, potentially revealing a site for future drug development.
19. Tunaru S, Kero J, Schaub A, et al.: PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 2003, 9:352-355. Elegant characterization (including creation of a knockout murine model) of the long-sought nicotinic acid receptor.
20. Barbier O, Torra IP, Duguay Y, et al.: Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vase Biol 2002, 22:717-726.
21. Watts GF, Barrett PH, Ji J, et al.: Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes 2003, 52:803-811.
22. Fruchart JC: Peroxisome proliferator-activated receptor-alpha activation and high-density lipoprotein metabolism. Am J Cardiol 2001, 88:24N-29N.
23. Guerin M, Le Goff W, Frisdal E, et al.: Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux. J Clin Endocrinol Metab 2003, 88:3738-3746.
24. Zhu D, Ganji SH, Kamanna VS, et al.: Effect of gemfibrozil on apolipoprotein B secretion and diacylglycerol acyltransferase activity in human hepatoblastoma (HepG2) cells. Atherosclerosis 2002, 164:221-228.
25. Wang TD, Chen WJ, Lin JW, et al.: Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. Atherosclerosis 2003, 170:315-323.
26. Tsimihodimos V, Kakafika A, Tambaki AP, et al.: Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins. J Lipid Res 2003, 44:927-934.
27. Paragh G, Seres I, Harangi M, et al.: The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease. Diabetes Metab 2003, 29:613-618.
28. Jones PH, Davidson MH, Stein EA, et al.: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003, 92:152-160. Head-to-head comparison of four statins with respect to lipid effects.
29. Bilz S, Wagner S, Schmitz M, et al.: Effects of atorvastatin versus fenofibrate on apoB-100 and apo A-I kinetics in mixed hyperlipidemia. J Lipid Res 2004, 45:174-185.
30. Bonn V, Cheung RC, Chen B, et al.: Simvastatin, an HMG-CoA reductase inhibitor, induces the synthesis and secretion of apolipoprotein AI in HepG2 cells and primary hamster hepatocytes. Atherosclerosis 2002, 163:59-68.
31. Qin S, Koga T, Ganji SH, et al.: Rosuvastatin stimulates apolipoprotein-AI synthesis but not HDL catabolism by human hepatoblastoma cells (Hep G2). Arterioscler Thromb Vasc Biol 2003, 23:55a.
32. Martin G, Duez H, Blanquart C, et al.: Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest 2001, 107:1423-1432.
33. Asztalos BF, Horvath KV, McNamara JR, et al.: Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. Atherosclerosis 2002, 164:361-369.
34. Ansell BJ, Navab M, Hama S, et al.: Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003, 108:2751-2756.
35. Deakin S, Leviev I, Guernier S, et al.: Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2. Arterioscler Thromb Vasc Biol 2003, 23:2083-2089.
36. Roberts AW, Thomas A, Rees A, et al.: Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions. Curr Opin Lipidol 2003, 14:567-573.
37. Van Wijk JP, de Koning EJ, Martens EP, et al.: Thiazolidinediones and blood lipids in type 2 diabetes. Arterioscler Thromb Vasc Biol 2003, 23:1744-1749. Meta-analysis of trials comparing the lipid effects of rosiglitazone and pioglitazone.
38. Bocher V, Plneda-Torra I, Fruchart JC, et al.: PPARs: transcription factors controlling lipid and lipoprotein metabolism. Ann N Y Acad Sci 2002, 967:7-18.
39. Le Goff W, Guerin M, Chapman MJ: Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia. Pharmacol Ther 2004, 101:17-38. Exhaustive review of the genetics, physiology, pathophysiology, and pharmacologie modulation of CETP.
40. Barter PJ, Brewer HB Jr, Chapman MJ, et al.: Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003, 23:160-167.
41. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, et al.: Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 2002, 105:2159-2165.
42. Clark RW, Sutfin TA, Ruggeri RB, et al.: Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol 2004; Jan 22 Promising report of a new CETP inhibitor with powerful HDL effects.
43. -/- mice, resulting in a profound increase in apoAI and HDL-C. Impiressively, atherosclerosis was significantly decreased in animals receiving DMPC for 8 weeks.
44. Bisgaier CL, Essenburg AD, Barnett BC, et al.: A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor. J Lipid Res 1998, 39:17-30.
45. Bays HE, McKenney JM, Dujovne CA, et al.: Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol. Am J Cardiol 2003, 92:539-543.
46. milano.
47. Kaul S, Rukshin V, Santos R, et al.: Intramural delivery of recombinant apolipoprotein A-IMilano/phospholipid complex (ETC-216) inhibits in-stent stenosis in porcine coronary arteries. Circulation 2003, 107:2551-2554.
48. milano. This work needs to be confirmed with more appropriate controls (including infusion of wild-type apoAI) but may represent a new direction in the treatment of atherosclerosis.
49. Navab M, Anantharamaiah GM, Reddy ST, et al.: Human apolipoprotein AI mimetic peptides for the treatment of atherosclerosis. Curr Opin Investig Drugs 2003, 4:1100-1104. A review of the theory behind, and animal data supporting, the use of apoAI mimetic peptides in the treatment of atherosclerosis.
50. Ou Z, Ou J, Ackerman AW, et al.: L-4F, an apolipoprotein A-1 mimetic, restores nitric oxide and superoxide anion balance in low-density lipoprotein-treated endothelial cells. Circulation 2003, 107:1520-1524.
51. Ou J, Ou Z, Jones DW, et al.: L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation 2003, 107:2337-2341.
52. Van Lenten BJ, Wagner AC, Anantharamaiah GM, et al.: Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide. Circulation 2002, 106:1127-1132.
53. Navab M, Anantharamaiah GM, Hama S, et al.: Oral administration of an apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 2002, 105:290-292.